Loading
Different companies' leftover-cancer blood tests disagree, and there is no shared yardstick. Public reference samples would let anyone check which test actually works.
Tumour-informed and tumour-naive ctDNA assays report different sensitivities at different variant allele fractions, and cross-assay comparisons are almost entirely vendor-run. A public reference material programme (synthetic and patient-derived contrived plasma at defined fractions, blinded rounds, published per-assay results) would do for MRD what proficiency schemes did for HER2 immunohistochemistry.
Shares Variant allele frequency (VAF), Natera, Guardant Health, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Shares Foresight Diagnostics, Variant allele frequency (VAF), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease.
Shares Variant allele frequency (VAF), Natera, Guardant Health, Biomarkers are not validated or standardised.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Biomarkers are not validated or standardised, MRD / molecular residual disease testing.
Shares Natera, Guardant Health, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease.
Shares Variant allele frequency (VAF), Natera, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Dormant cells and minimal residual disease.
Shares Adaptive Biotechnologies, NGS-based MRD (clonoSEQ and molecular MRD), Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
Shares Natera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.